Compositions and methods for treating cancer with DuoCARs
AssigneeLentigen Technology, Inc.
InventorsRimas J. Orentas, Dina Schneider, Waleed M. Haso, Stefan Miltenyi, Boro Dropulic
Life of this patent
Estimating the term…
Abstract
Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.
Claims8
An immunotherapy composition comprising:
- at least one multicistronic vector comprising a promoter operably linked to a multi-cistronic nucleic acid sequence encoding two or more functional CARs comprising an extracellular antigen binding domain, a transmembrane domain, one or more non-identical intracellular signaling motifs, wherein each of the encoded two or more functional CARs comprises a non-identical amino acid sequence that is independently selected from the group consisting of the amino acid sequence of SEQ ID NO:110, 112, 114, and 116;
- and wherein the at least one multi-cistronic vector is used to genetically modify one or more lymphocyte populations.
A pharmaceutical composition comprising an antitumor effective amount of a population of isolated human lymphocyte cells, wherein the cells of the population include cells comprising (a) nucleic acid molecules encoding at least one multicistronic vector;
- (b) wherein the at least one multicistronic vector comprises a promoter operably linked to a multicistronic nucleic acid sequence encoding two or more functional CARs comprising an extracellular antigen binding domain, a transmembrane domain, one or more non-identical intracellular signaling motifs, wherein each of the encoded two or more functional CARs comprises a non-identical amino acid sequence that is independently selected from the group consisting of the amino acid sequence of SEQ ID NO:
- 110, 112, 114, and 116, wherein the at least one multicistronic vector is used to genetically modify the population of human lymphocyte cells.
Dependencies are inferred from the claim text.